RASONQUE turned its first commercial quarter into a 622% revenue beat. Management is telling investors not to extrapolate: expanded-access transfers, pent-up demand and initial channel stocking all inflated the quarter.
Latest Activity
Mad Money w/ Jim Cramer 10/27/26
- Cramer rejects the AI all-clear despite Broadcom arranging $63 billion in financing for Anthropic compute
- Meta's $25 billion equity raise was five times oversubscribed, but the $60 billion at-the-market program worries him
- CoreWeave bonds reaching a 15% yield flagged as the sector's unresolved weak spot
- Caller questions on Micron volatility and Revolution Medicines' pancreatic cancer drug
The bull case for data centers today rested on financing rather than profits, and Cramer wants to hear a customer say the chips are minting money before calling it clear. He expects Meta's at-the-market selling to weigh on the stock as supply hits at the wrong moments, with borrowing costs into a Fed decision the swing factor for everything levered to the buildout.
RVMD Coverage
Top Biopharma Analyst Sees Biotech M&A Market Reopening After a Long Freeze
A top Barclays biopharma analyst says the forces that froze biotech dealmaking are breaking apart, and the pharma giants shopping for acquisitions have very specific reasons they cannot afford to stop.
Why Revolution Medicines May Be Big Pharma’s Next Takeover Target
RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math…
5 Stock Setups Where Wall Street Sees the Most Upside Right Now
The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particularly for this group of stocks we have uncovered. JPMorgan just tagged CECO Environmental…
After Apogee, 3 More Biotech Buyout Targets Wall Street Can’t Stop Watching
Big Pharma's patent cliffs are forcing acquirers to hunt for revenue-producing biotech assets before rivals snap them up, and three names keep surfacing in deal speculation. One already has a natural buyer…
Stock Market Live April 13: S&P 500 (SPY) Back in the Red as Oil Gushes Higher
Live Updates Nike Was Downgraded Again8:30am ETWall Street has apparently lost its patience with Nike. After pushing recovery hopes out a bit further with its last batch of earnings, analysts at HSBC…
These 5 Biotechs Could Be the Next Big GLP-1 Acquisition Target
The GLP-1 revolution has reshaped biopharma M&A strategy. With Novo Nordisk and Eli Lilly generating tens of billions in annual obesity drug revenue, large-cap acquirers are scouring the biotech landscape for the…
Prediction: This Pharma Stock Will Be the Best Performer in 2025
Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big expectations for Viking Therapeutics.
Insiders Are Loving These 6 Stocks Right Now
The most notable insider purchases of stock in the past week were in biotech and energy companies, as well as a specialty retailer.
Wednesday’s Top Analyst Upgrades and Downgrades: Broadcom, Clean Energy Fuels, Dish Network, Occidental Petroleum, Workday and More
Wednesday's top analyst upgrades and downgrades included Broadcom, Clean Energy Fuels, Dish Network, First Republic Bank, Gaming and Leisure Properties, Occidental Petroleum, Revolution Medicines, Veeva Systems and Workday.
Friday’s Top Analyst Upgrades and Downgrades: AT&T, Exxon Mobil, Hasbro, Moderna, Snap, Under Armour and More
Friday's top analyst upgrades and downgrades included AT&T, Exxon Mobil, Hasbro, Juniper Networks, Moderna, Palo Alto Networks, Snap, Teva Pharmaceutical, Under Armour and Zscaler.
Top Analyst Upgrades and Downgrades: Oil E&Ps, Amex, ADT, Gilead, Logitech, PACCAR, Regions, Stamps.com, Vivint Smart Home and More
Monday's top analyst upgrades, downgrades and initiations included American Express, ADT, Gilead Sciences, Logitech, PACCAR, Regions Financial, Stamps.com and Vivint Smart Home.